Availability of data and material
All data used in the present study is publicly available at the referenced data repositories.
Code availability
All analyses were performed with R programming language. Code is available upon request.
References
Pacak K, Eisenhofer G, Ahlman H et al (2007) Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 3:92–102
Lenders JW, Duh QY, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:1915–1942. https://doi.org/10.1210/jc.2014-1498
Lefebvre M, Foulkes WD (2014) Pheochromocytoma and paraganglioma syndromes: genetics and management update. Curr Oncol 21:e8–e17
Hendry S, Salgado R, Gevaert T et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: Part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol 24:235–251
Bremnes RM, Al-Shibli K, Donnem T et al (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6:824–833
Thorsson V, Gibbs DL, Brown SD et al (2018) (2019) The Immune Landscape of Cancer. Immunity 48(4):812–830.e14 (published correction appears in Immunity. 51(2):411–412)
Tamborero D, Rubio-Perez C, Muiños F et al (2018) A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin Cancer Res 24(15):3717–3728
Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR et al (2017) Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31(2):181–193
Newman AM, Steen CB, Liu CL et al (2019) Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol 37:773–782
Porta-Pardo E, Godzik A (2016) Mutation drivers of immunological responses to cancer. Cancer Immunol Res 4(9):789–798
Hadoux J, Terroir M, Leboulleux S et al (2017) Interferon-alpha treatment for disease control in metastatic pheochromocytoma/paraganglioma patients. Horm Cancer 8(5–6):330–337
Kirkwood JM, Bender C, Agarwala S et al (2002) Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 20(17):3703–3718
Jayasingam SD, Citartan M, Thang TH, Mat Zin AA, Ang KC, Ch'ng ES (2020) Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front Oncol 9:1512
Ohue Y, Nishikawa H (2019) Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci 110:2080–2089
Lee C, Jeong H, Bae Y et al (2019) Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. J Immunother Cancer 7:147
Tay RE, Richardson EK, Toh HC (2020) Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms. Cancer Gene Ther. https://doi.org/10.1038/s41417-020-0183-x
Zhao X, Lei Y, Li G, Cheng Y, Yang H et al (2019) Integrative analysis of cancer driver genes in prostate adenocarcinoma. Mol Med Rep 19:2707–2715
Kim N, Hong Y, Kwon D, Yoon S (2013) Somatic mutaome profile in human cancer tissues. Genomics Inform 11(4):239–244
Funding
Not applicable. No funding was received for this study.
Author information
Authors and Affiliations
Contributions
SB: conceptualization, methodology, software, visualization, investigation, writing—reviewing and editing.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to declare.
Research involving human participants and/or animals
This article does not contain any experiments with human participants performed by the authors.
Informed consent
For this type of study, formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Batchu, S. Age-related differences of immune infiltrates in pheochromocytomas and paragangliomas. J Endocrinol Invest 44, 1543–1546 (2021). https://doi.org/10.1007/s40618-020-01443-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40618-020-01443-x